---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-107634"
form_type: "8-K"
ticker: "ALUR"
cik: "0001964979"
company_name: "ALLURION TECHNOLOGIES, INC."
filed_at: "2025-08-13T23:59:59+00:00"
generated_at: "2026-05-17T14:02:22.714970+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Allurion Q2 revenue plunges to $3.4M; restructure, potential restatement of non-cash items

## Summary
- Q2 2025 revenue $3.4M, down 71% YoY from $11.8M; gross margin 74% vs 76%.
- Operating loss improved to $7.0M from $9.3M YoY; cash $12.7M as of June 30.
- Restructuring charges ~$1.5M in Q3 2025; FY2025 guidance being re-evaluated.
- Potential restatement of non-cash OCI/other income related to RIFA and convertible notes; no impact on revenue, gross margin, opex, or cash.
- New strategy: focus on low-dose GLP-1 combo therapy, muscle mass maintenance; FDA PMA accepted for Allurion Balloon; term sheet signed for drug-eluting balloon.

## SEC filing metadata
- accession: 0000950170-25-107634
- form_type: 8-K
- ticker: ALUR
- cik: 0001964979
- company_name: ALLURION TECHNOLOGIES, INC.
- filed_at: 2025-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1964979/000095017025107634/0000950170-25-107634-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1964979/000095017025107634/alur-20250813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-107634
- JSON: https://secwatch.observer/filing/0000950170-25-107634.json
- Plain text: https://secwatch.observer/filing/0000950170-25-107634.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.